Please assess the completion status of the following clinical trial:

Trial Title: Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients, aged 18 to 75 years.~* Diagnosis of Bipolar Disorder (Bipolar I or Bipolar II).~* Current diagnosis of Generalized Anxiety Disorder (GAD).~* Participants must be on at least one of the following mood stabilizers at steady dose for at least 4 weeks prior to randomization: lithium with blood levels between 0.4-1.4 meq/L, valproic acid/divalproate sodium (with levels between 50-150 ugm/dl) carbamazepine (blood levels between 4-12 mcg/ml), or lamotrigine (dosed 50-400 mg/day).~Exclusion Criteria:~* Pregnant or lactating women or others not using acceptable means of birth control (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, implanted progesterone rods stabilized for at least 3 months).~* Patients with current or history of schizophrenia, or patients with current mania, hypomania at study entry. Lifetime psychosis and dementia are exclusionary.~* Patients with current obsessive-compulsive disorder or posttraumatic stress disorder are excluded.~* Patients with a history of alcohol or substance abuse or dependence within the last three months.~* Patients with significant unstable medical illness likely to result in hospitalization or acute medical care. In addition, patients with an established diagnosis of diabetes mellitus are excluded.~* Current cognitive behavioral therapy directed toward the treatment of generalized anxiety disorder.~* History of hypersensitivity to or lack of response to ziprasidone.~* Concomitant treatment with other typical or atypical antipsychotics; patients should be off other typical or atypical antipsychotics for at least one week prior to study baseline.~* Patients with significant suicidal ideation or who have enacted suicidal behaviors within 3 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.~* Patients who have had a psychiatric hospitalization (including for bipolar disorder) in the past 3 months are excluded.~* Seizure disorders with the exception of a history of febrile seizures if they occurred during childhood, were isolated, and did not recur in adulthood.~* History of Neuroleptic Malignant Syndrome.~* Individuals with current clinically significant orthostatic hypotension are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ziprasidone (Type: EXPERIMENTAL): Ziprasidone will be dosed on a twice daily (BID) basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day, for 8 weeks. This time period reflects the rapid onset of effect seen in studies of atypical antipsychotics, but allows time for a potentially longer response for some anxiety symptoms.
- Placebo Capsules (Type: PLACEBO_COMPARATOR): Identical placebo capsules will be dosed on a BID basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).